EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human Proteome Microarray identifies autoantibodies to tumor‐associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma

Qian Yang, Hua Ye, Guiying Sun, Keyan Wang, Liping Dai, Cuipeng Qiu, Jianxiang Shi, Jicun Zhu, Xiao Wang, Peng Wang iD

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Qian Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The identification of the high‐efficiency and non‐invasive biomarkers for hepatocellular carcinoma (HCC) detection is urgently needed. This study aims to screen out potential autoantibodies to tumor‐associated antigens (TAAbs) and to assess their diagnostic value for HCC. Fifteen potential TAAbs were screened out from the Human Proteome Microarray by 30 HCC sera and 22 normal control sera, of which eight passed multiple‐stage validations by ELISA with a total of 1625 human serum samples from normal controls (NCs) and patients with HCC, liver cirrhosis, chronic hepatitis B, gastric cancer, esophageal cancer, and colorectal cancer. Finally, an immunodiagnostic model including six TAAbs (RAD23A, CAST, RUNX1T1, PAIP1, SARS, PRKCZ) was constructed by logistic regression, and yielded the area under curve (AUC) of 0.835 and 0.788 in training and validation sets, respectively. The serial serum samples from HCC model mice were tested to explore the change in TAAbs during HCC formation, and an increasing level of autoantibodies was observed. In conclusion, the panel of six TAAbs can provide potential value for HCC detection, and the strategy to identify novel serological biomarkers can also provide new clues in understanding immunodiagnostic biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMiceAnimalsAutoantibodiesProteomeBiomarkers, TumorAntigens, NeoplasmPeptide Initiation FactorsRNA-Binding ProteinsDNA-Binding ProteinsDNA Repair Enzymes

Stichwörter der Autor:innen

Human Proteome Microarraybiomarkerdiagnosishepatocellular carcinoma

Substanzen

AutoantibodiesProteomeBiomarkers, TumorAntigens, NeoplasmPAIP1 protein, humanPeptide Initiation FactorsRNA-Binding ProteinsRAD23A protein, humanDNA-Binding ProteinsDNA Repair Enzymes

Autor:innen und Institutionen

  • The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.
  • Department of Prenatal Diagnosis Center, The Third Affiliated Hospital of Zhengzhou University, China.
  • Department of Epidemiology and Health Statistics and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, China.
  • Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, China.

ORCID-Profile: Peng Wang

Zitieren

APA

Yang, Q., Ye, H., Sun, G., Wang, K., Dai, L., Qiu, C., Shi, J., Zhu, J., Wang, X., & Wang, P. (2023). Human Proteome Microarray identifies autoantibodies to tumor‐associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13371

Vancouver

Yang Q, Ye H, Sun G, Wang K, Dai L, Qiu C, et al. Human Proteome Microarray identifies autoantibodies to tumor‐associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. Molecular Oncology. 2023. doi:10.1002/1878-0261.13371

BibTeX
@article{Yang2023,
  author = {Yang, Qian and Ye, Hua and Sun, Guiying and Wang, Keyan and Dai, Liping and Qiu, Cuipeng and Shi, Jianxiang and Zhu, Jicun and Wang, Xiao and Wang, Peng},
  title = {Human Proteome Microarray identifies autoantibodies to tumor‐associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13371}
}
Kostenlos starten →